Literature DB >> 8217831

Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides.

A Greinacher1, I Michels, U Liebenhoff, P Presek, C Mueller-Eckhardt.   

Abstract

The interaction of sulphated oligosaccharides (SO) with platelets and the antibody of heparin-associated thrombocytopenia (HAT type II) was investigated. 3H-heparin binding to platelets was inhibited by different SO, depending on their grade of sulphation. Dextran sulphate, pentosan polysulphate, and heparin were more effective than were LMW heparins. De-N-sulphated heparin and a LMW heparinoid (Org 10172) had no effect. Platelets preincubated with high-grade SO and washed, released serotonin in the presence of HAT sera without additional heparin. Platelets preincubated with HAT sera and then washed were not activated when heparin was added. Only high-grade SO which inhibited heparin binding to platelets caused platelet activation with HAT sera. However, low- and high-grade SO in high concentrations (0.11 g/l) inhibited serotonin release induced by HAT sera and heparin. 32P-phosphorylation of platelet proteins was enhanced by HAT-IgG and heparin and by heat-aggregated IgG, and was inhibited by the moab IV.3. High SO concentrations inhibited only the effect of HAT-IgG and not that of aggregated IgG. We assume that the antigen in HAT involves a releasable platelet protein with a binding site for SO. This was corroborated by studies with an anti-platelet factor 4 antibody causing Fc-receptor dependent platelet activation inhibitable by high SO concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8217831     DOI: 10.1111/j.1365-2141.1993.tb03150.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Heparin-Induced thrombocytopenia: minimising the risks in the elderly patient.

Authors:  B Tardy-Poncet; B Tardy
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

Review 2.  Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

Authors:  T E Warkentin
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

Review 3.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response.

Authors:  A Winder; Y Shoenfeld; R Hochman; G Keren; Y Levy; A Eldor
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

Review 5.  [Heparin induced thrombocytopenia. A frequently unrecognised complication after major orthopedic surgery].

Authors:  S M Picker; B S Gathof
Journal:  Orthopade       Date:  2004-11       Impact factor: 1.087

6.  Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia.

Authors:  Preeyanat Vongchan; Weerasak Nawarawong; Robert J Linhardt
Journal:  Am J Clin Pathol       Date:  2008-09       Impact factor: 2.493

Review 7.  A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Authors:  D M Arnold; S Kukaswadia; I Nazi; A Esmail; L Dewar; J W Smith; T E Warkentin; J G Kelton
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

Review 8.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.